

# Genetic investigation of challenging cardiovascular disease predominant in women



*The Two Fridas, 1939*  
Museo de arte moderno, Mexico

**Nabila Bouatia-Naji, PhD**


Email: [nabila.bouatia-naji@inserm.fr](mailto:nabila.bouatia-naji@inserm.fr)

Twitter: @n\_bouatianaji

# Cardiovascular disease #1 killer

WHO Source

17 million deaths





# Proportion of deaths due to CVD causes in Europe



Man and woman, Fernando Botero


CVD is 49% of causes in women

Breast Cancer: 3%




# Cardiovascular disease: inflammation is key!

Dialogue between monocytes, macrophages, in response to lipids accumulations



Atherosclerotic plaque evolution

# CVD is Diverse - lipids accumulation and the progress of inflammation are not always reported




Libby et al., Nature Reviews, Disease Primers 2019

## Risk Factors:

- Smoking
- Lack of exercise
- Diet
- Obesity
- High blood pressure
- High LDL or low HDL cholesterol levels
- Age


- Underdiagnosed conditions
- Secondary hypertension
- Bad responders to current treatments
- Unexpected events, no typical risk factors

# Fibromuscular dysplasia (FMD)



- Succession of stenoses and aneurysms of medium arteries
- Atypical clinical presentation (e.g no dyslipidemia, no obesity)
- Complex imaging-based diagnosis
- Underdiagnosed (stroke or resistant hypertension, often incidentally in 3-4% of kidney donors)
- Diagnosed in 50% of SCAD cases, a rare MI event



Angiography



Olin et al Circ 2012  
Touzé E et al, Int J Stroke 2010  
Plouin Hypertension 2017  
McKenzie J Vasc Interv Radiol 2013

# Spontaneous coronary artery dissection (SCAD)

Optical computed tomography (OCT)



- **Nonatherosclerotic** acute coronary syndrome: few risk factors (no dyslipidemia, healthy lifestyle)
- Formation of intramural hematoma and/ or intimal disruption
- Age of event ~ 45-50 years → younger than classical heart disease

Motreff EuroIntervention 2017  
Tweet Curr Cardiol Rep 2016  
Saw JACC 2016  
Tweet JACC 2017

# FMD and SCAD: female neglected and under-investigated arterial diseases

- 80 to 90% of patients are women 44-55 years
- FMD is a cause of renal hypertension in ~ 10% of cases (diagnosis delay ~10 years)
- SCAD represents 25-33% of myocardial infarction in women < 60 yrs
- Awareness among cardiologists is increasing




*The Two Fridas, 1939*  
Museo de arte moderno, Mexico

Motreff EuroIntervention 2017  
Hayes Circ 2018  
Plouin Hypertension 2017  
Olin Circ 2012




# SCAD and FMD has unknown pathophysiology




## Healthy Artery




## Stenosis/ Aneurysm




## Dissection



- Mechanical Stress
- Hormones fluctuation
- Smoking
- **Genetic factors**



# ROSALIND Research Program to Investigate SCAD and FMD




FMD / SCAD Case Control GWAS  
(Exome and Target sequencing)

Gene  
Prioritisation

Global Expression  
Renal Arteries

Aim1: Decipher the genetic basis of FMD and SCAD




Healthy


FMD

Aim2: Study the Functional Relevance of FMD Risk Loci


Differential  
expression profiling



Genomic Interactions  
Open Chromatin



Primary and iPSC  
induced SMCs



Adhesion/migration

High Throughput  
Functional Genomics

In Vitro Functional  
validation

Renal Arteries  
Transcriptomics

Aim3: Explore the Link between FMD Genes and Vascular Function

New actors of vascular  
physiopathology

To contribute filling an important existing gap in the investigation of women specific cardiovascular diseases

# The challenges of the genetics of FMD and SCAD


## Study populations

- Small families (sibs, mother/daughter)
- No large scale case control studies (>10K cases) to compensate the clinical heterogeneity

## Physiopathology

- Most of knowledge: rare syndromes (TGF-beta, ECM biology)
- Lack of an animal model

Sorry, but we small animals do not develop FMD and dissection




## Environmental exposure



- Mechanical stress? Hormones? Others

## Genetic model ?


# PTGIR rare variants are enriched in FMD and impair receptor activation *in vitro*



- Exomes Seq 30 FMD patients
- 4 Rare LoF (1,325 FMD, P=0.0008 vs. gnomAD)
- 2 Rare LoF (843 SCAD, P=0.12)




Prostacyclin receptor  
a well-known player in vascular biology




- Strongly expressed in the lungs and vasculature
- Validated therapeutic target in pulmonary arterial hypertension


# Genetic investigation of FMD leveraging GWAS, genomic annotation and expression in arteries




SNP-based heritability = 0.29, polygenic



Genomic association context




Functional annotation




Genotype / expression correlation

\*LRP1: LDL receptor related protein 1


# Genes near FMD loci are involved in cell contractility





Gene expression by sex in arteries (GTEx database)



## Cytoskeleton




## Calcium transport



## Contractile function of vascular cells in arteries

# Association involving different alleles in FMD and SCAD vs. CVD involving atherosclerosis



# Summary

- FMD and SCAD **atypical neglected** CVD predominant in women
- Evidence for complex genetic inheritance involving rare mutations (*PTGIR*) and common risk loci through GWAS (e.g *LRP1*, *PHACTR1*)
- Genes mutated or near FMD GWAS loci involve vasodilation, cytoskeleton biology, and calcium dependant contractile function
- *PHACTR1* is one first example of **shared genetic risk allele between FMD and SCAD**, opposite to risk allele involving more common atherosclerosis-linked CVD
- Upcoming GWAS for SCAD: not all loci are shared with FMD
- Increasing awareness: **CVD in women presents differently**, evolves differently, to be managed/treated differently?



# Team: Genetics to Understand CVD in Women



## French and International Networks

### FMD

X Jeunemaitre, Genetics Dept, HEGP  
M Azizi,/ L Amar, HTN Dept, HEGP  
A Persu/ M Vikkula, UCL, Belgium  
A Januszewicz, Warsaw, Poland  
J Kovacic/J Olin, Mount Sinai, NY, USA  
H Gornik, Cleveland Clinic, USA  
S Ganesh, U Michigan, USA  
I Kullo, Mayo Clinic, USA



### SCAD

P Mottreff, CHU C Ferrand, France  
D Adlam, Leicester University, UK  
S Hayes, Mayo Clinic, USA  
T Olsson, Mayo Clinic, USA  
B Graham, V Chang Institute, AU

